GLP-1 receptor agonists × glycemic control

TrialDiabetologia2007

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.

M A Nauck et al.PubMed ↗Publisher ↗

What the trial testedas reported · 501 people · 2007

Range includes no effect

No clear effect on glycemic control

−0.15−0.32 to +0.01

As reported

difference −0.15, 95% CI −0.32 to 0.01

Not counted

Probably lowered glycemic control

−5.40−5.90 to −5.00

As reported

difference −5.4, 95% CI −5.90 to −5.00

Two numbers in the abstract

the abstract, start to end

aspart -0.89 +/- 0.06%; difference -0.15 [95% CI -0.32 to 0.01]%).

gained weight [between-group difference -5.4 (95% CI -5.9 to -5.0) kg].

← favours treatmentfavours comparator →
could be chance
Glycemic control
−0.15−0.32 to 0.01
Glycemic control
−5.4−5.90 to −5.00
GLP-1 receptor agonistsInsulinGlycemic control

GLP-1 receptor agonists × glycemic controlhelps?replicated

unlikelylikely
0.910.91 without it

Insulin × glycemic controlhelps?mixed

unlikelylikely
0.500.50 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 6

130 papers cite itlatest 60 shown

2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2022
2023
2025
2026
this paperpooled ittrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 17160407